These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 16754809)
41. Characteriation of clinical data packages using foreign data in new drug applications in Japan. Tanaka M; Nagata T Clin Pharmacol Ther; 2008 Sep; 84(3):340-6. PubMed ID: 17786162 [TBL] [Abstract][Full Text] [Related]
43. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill. Ochs A Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540 [No Abstract] [Full Text] [Related]
44. Stroke treatment--light at the end of the tunnel? Garber K Nat Biotechnol; 2007 Aug; 25(8):838-40. PubMed ID: 17687351 [No Abstract] [Full Text] [Related]
45. John Dillinger and clinical trials. Casey R Can J Urol; 2007 Oct; 14(5):3715. PubMed ID: 17949530 [No Abstract] [Full Text] [Related]
52. Drug review "behind the curtain": a response to Professor Struve. O'Reilly JT Cornell Law Rev; 2008 Jul; 93(5):1075-90. PubMed ID: 18618971 [No Abstract] [Full Text] [Related]
53. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297 [TBL] [Abstract][Full Text] [Related]
55. A new approach to drug development. Frangioni JV N Engl J Med; 2006 Nov; 355(19):2046; author reply 2046. PubMed ID: 17099947 [No Abstract] [Full Text] [Related]
56. The time is ripe. Mortimer M Nature; 2007 Jun; 447(7146):884. PubMed ID: 17593575 [No Abstract] [Full Text] [Related]
57. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006. Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891 [TBL] [Abstract][Full Text] [Related]
58. 80% of China's clinical trial data are fraudulent, investigation finds. Woodhead M BMJ; 2016 Oct; 355():i5396. PubMed ID: 27707716 [No Abstract] [Full Text] [Related]
59. [No one is expected to ignore... the legal status of drug promotional studies]. Cereghetti A Rev Med Suisse; 2006 Oct; 2(82):2307-10. PubMed ID: 17124859 [No Abstract] [Full Text] [Related]
60. Poor enforcement could jeopardize China's drug innovation policy. Jia H Nat Biotechnol; 2006 Oct; 24(10):1182-3. PubMed ID: 17033642 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]